Analysts Offer Predictions for NAMS FY2026 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will earn ($2.25) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $42.00 target price on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share.

NAMS has been the topic of several other research reports. Needham & Company LLC reduced their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research note on Tuesday. They set a “buy” rating and a $44.00 price objective on the stock. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $20.16 on Tuesday. The company has a market capitalization of $2.26 billion, a PE ratio of -10.72 and a beta of -0.03. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29. The company’s 50 day moving average price is $17.82 and its two-hundred day moving average price is $20.86.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The company had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C lifted its holdings in NewAmsterdam Pharma by 378.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after buying an additional 3,412,590 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after acquiring an additional 3,061,224 shares in the last quarter. Wellington Management Group LLP boosted its holdings in NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock valued at $59,499,000 after acquiring an additional 2,222,900 shares in the last quarter. Capital International Investors purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at $53,007,000. Finally, Alliancebernstein L.P. bought a new position in NewAmsterdam Pharma in the 4th quarter worth $47,752,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director James N. Topper bought 1,135 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the acquisition, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This trade represents a 0.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.